- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Cramer's outlook on drug stocks.
Despite a Phase 3 stumble, BMY stock is holding up.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Late stage trials failed to show significant statistical efficacy.